Literature DB >> 19363331

Etravirine-raltegravir, a marked interaction in HIV-1-infected patients: about four cases.

Amélie Ménard, Caroline Solas, Saadia Mokthari, Sylvie Bregigeon, Marie-Pierre Drogoul, Catherine Tamalet, Bruno Lacarelle, Isabelle Poizot Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19363331     DOI： 10.1097/QAD.0b013e328329915f

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  8 in total

1.  Clinical Use of Inhibitors of HIV-1 Integration: Problems and Prospects.

Authors:  S P Korolev; Yu Yu Agapkina; M B Gottikh
Journal:  Acta Naturae       Date:  2011-07       Impact factor: 1.845

2.  Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.

Authors:  Rob Ter Heine; Jan Willem Mulder; Eric C M van Gorp; Jiri F P Wagenaar; Jos H Beijnen; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2010-05       Impact factor: 4.335

3.  Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.

Authors:  Ivy Song; Julie Borland; Sherene Min; Yu Lou; Shuguang Chen; Parul Patel; Toshihiro Wajima; Stephen C Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2011-05-09       Impact factor: 5.191

4.  Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.

Authors:  Susan L Ford; Elizabeth Gould; Shuguang Chen; Yu Lou; Etienne Dumont; William Spreen; Stephen Piscitelli
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

Review 5.  Raltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics.

Authors:  Kajal B Larson; Jennifer R King; Edward P Acosta
Journal:  Adolesc Health Med Ther       Date:  2013-08-27

6.  Extensive virologic and immunologic characterization in an HIV-infected individual following allogeneic stem cell transplant and analytic cessation of antiretroviral therapy: A case study.

Authors:  Nathan W Cummins; Stacey Rizza; Mark R Litzow; Stephane Hua; Guinevere Q Lee; Kevin Einkauf; Tae-Wook Chun; Frank Rhame; Jason V Baker; Michael P Busch; Nicolas Chomont; Patrick G Dean; Rémi Fromentin; Ashley T Haase; Dylan Hampton; Sheila M Keating; Steven M Lada; Tzong-Hae Lee; Sekar Natesampillai; Douglas D Richman; Timothy W Schacker; Stephen Wietgrefe; Xu G Yu; Joseph D Yao; John Zeuli; Mathias Lichterfeld; Andrew D Badley
Journal:  PLoS Med       Date:  2017-11-28       Impact factor: 11.069

Review 7.  Drug-drug interactions with raltegravir.

Authors:  David M Burger
Journal:  Eur J Med Res       Date:  2009-11-24       Impact factor: 2.175

8.  Antiretroviral drug interactions: overview of interactions involving new and investigational agents and the role of therapeutic drug monitoring for management.

Authors:  R Chris Rathbun; Michelle D Liedtke
Journal:  Pharmaceutics       Date:  2011-10-21       Impact factor: 6.321
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.